The tale of a booming federal drug discount program, which pharma companies have sought to curtail, has often been told but rarely with new numbers.
Now, the drug pricing gurus at IQVIA say their latest data shows that the program, known as 340B and once designed to give massive discounts to only a select number of outpatient drugs for only a select few health care providers, has ballooned to $93.6 billion in sales in 2021, which is about 15% of the total $668.3 billion in pharma sales for the year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,